Glycated haemoglobin testing is used to measure average blood sugar levels over extended periods. The HbA1c test is a blood test that is primarily used to diagnose prediabetes and diabetes and to monitor long-term blood sugar control in people with diabetes. Glycated haemoglobin forms when blood sugar attaches itself to the haemoglobin in red blood cells. This test provides average blood sugar levels for the past 2 to 3 months, while a regular blood sugar test checks levels at that moment. The HbA1c test has many benefits over routine blood glucose monitoring, as it eliminates the need for fasting and factors in fluctuations in blood sugar levels. Rising cases of diabetes worldwide has increased the use of this test to closely monitor blood sugar levels in diagnosed patients over long periods of time.
The glycated haemoglobin testing market is estimated to be valued at USD 239 Mn in 2024 and is expected to reach USD 426 Mn by 2031, growing at a compound annual growth rate (CAGR) of 8.6% from 2024 to 2031.
Key Takeaways
Key players operating in the Glycated Haemoglobin Testing are Abbott Laboratories, Bio-Rad Laboratories, Danaher Corporation (Beckman Coulter), EKF Diagnostics Holdings plc, F. Hoffmann-La Roche Ltd., SEBIA, Trinity Biotech and Polymer Technology Systems.
Growing prevalence of diabetes around the world is a major factor spurring demand for glycated haemoglobin testing. As per IDF Diabetes Atlas 2021, around 537 million adults were living with diabetes in 2021 globally and the number is expected to rise to 783 million by 2045. Stringent regulatory guidelines regarding diabetes diagnosis and management are also contributing to Glycated Haemoglobin Testing Market growth.
Technological advancements are witnessing in HbA1c testing devices. Point-of-care testing devices are gaining traction as they enable quick in-office testing and reduce turnaround time for results. Home based self-testing kits are also being developed to enable patients to conveniently monitor their blood sugar levels without visiting diagnostic centers.
Market Trends
Increasing adoption of personal diabetes management devices - Continuous glucose monitoring (CGM) systems and smart insulin pens that connect to mobile apps are being increasingly used. Data from these devices help analyze HbA1c trends over time and make timely therapy changes.
Growing demand for alternate biomarkers - Fructosamine and Glycated Albumin are emerging as alternate biomarkers to HbA1c for glycemic control assessment. They are being evaluated for advantages over HbA1c in conditions like abnormal red blood cell lifespan.
Market Opportunities
Emerging markets in Asia Pacific and Latin America hold significant growth opportunities. Rapid economic development and growing medical infrastructure in these regions will boost market expansion.
Increasing healthcare expenditures on diabetes management in developed countries also provides opportunities. Government initiatives for diabetes screening and control programs will augment the demand.
Impact of COVID-19 on Glycated Haemoglobin Testing Market Growth
The outbreak of COVID-19 pandemic has significantly impacted the growth of glycated haemoglobin testing market globally. During the initial phase of the pandemic, many elective procedures and routine healthcare visits were postponed to focus on critical COVID-19 patients. This led to a decline in the number of glycated haemoglobin tests being conducted. However, as glycated haemoglobin testing plays a crucial role in managing diabetes, healthcare facilities ensured such patients continue to receive requiredcare while following necessary safety protocols. With the introduction of vaccines and normalization of healthcare services, the market is recovering gradually.
Market players are focusing on leveraging telehealth and developing home-use testing kits to bridge accessibility gaps amid pandemic. They are promoting self-monitoring and improving online portals for test results and consultations. Several point-of-care testing devices with rapid results are being launched. However, affordability remains a concern in low and middle-income countries severely impacted by the pandemic. Governments and organizations are collaborating to enhance access to essential diabetes care services and supplies. Overall, with resumption of routine checkups and prioritizing diabetes management, the market is anticipated to witness steady growth over the forecast period.
Geographical regions with concentrated market value
In terms of value, North America dominates the glycated haemoglobin testing market owing to the presence of major market players, high healthcare spending, and growing diabetic population. Meanwhile, Asia Pacific is projected to be the fastest-growing regional market by 2028. This is attributed to increasing awareness about diabetes care, healthcare reimbursements, and accessibility of innovative testing technologies even in remote areas. Further, economic development and rising discretionary incomes are positively influencing the market growth across developing nations in Asia Pacific and Latin America regions.
Get More Insights On- Glycated Haemoglobin Testing Market
Get This Report in Japanese Language: グリコヘモグロビン検査市場
Get This Report in Korean Language: 당화혈색소 검사 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.
(https://www.linkedin.com/in/ravina-pandya-1a3984191)